Skip to main content
Premium Trial:

Request an Annual Quote

Med BioGene and Duke to Jointly Develop Biomarkers for Lymphoma, Leukemia

NEW YORK (GenomeWeb News) – Med BioGene this week said it has entered into a research collaboration and option agreement with Duke University to further develop and validate genetic biomarkers for lymphoma and leukemia.
 
Under the terms of the collaboration, which will use MBI’s gene expression-profiling system, Duke will provide MBI a certain number of samples from patients with clinically confirmed lymphoma and leukemia for genetic analysis.
 
Duke and MBI will analyze those results, and Duke will grant MBI an option to acquire exclusive worldwide licensing rights to the intellectual property developed under the collaboration.
 
MBI will reimburse Duke for certain expenditures, and then pay undisclosed royalties to Duke on revenue received from product sales. Duke will be entitled to publish the results of the research, subject to review by MBI.
 
Financial terms of the agreement were not disclosed.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.